IDEXX Laboratories Inc. (IDXX)

IDEXX Laboratories Inc. (IDXX $528.79)
- $528.79 P/E (TTM): 38.91X Cap: $41.71B
- View IDXX Profile
- View Questions on IDXX

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Intuitive Surgical Inc. (ISRG $421.12)
- $421.12 P/E (TTM): 51.17X Cap: $149.14B
- View ISRG Profile
- View Questions on ISRG
Vertex Pharmaceuticals Incorporated (VRTX $436.95)
- $436.95 P/E (TTM): 25.98X Cap: $110.90B
- View VRTX Profile
- View Questions on VRTX
AbbVie Inc. (ABBV $210.39)
- $210.39 P/E (TTM): 103.64X Cap: $371.71B
- View ABBV Profile
- View Questions on ABBV
Johnson & Johnson (JNJ $226.71)
- $226.71 P/E (TTM): 20.55X Cap: $545.74B
- View JNJ Profile
- View Questions on JNJ
Eli Lilly and Company (LLY $1,004.92)
- $1,004.92 P/E (TTM): 43.79X Cap: $946.37B
- View LLY Profile
- View Questions on LLY
Merck & Company Inc. (MRK $111.38)
- $111.38 P/E (TTM): 15.3X Cap: $275.08B
- View MRK Profile
- View Questions on MRK
iShares Biotechnology ETF (IBB $166.83)
- $166.83 P/E (TTM): 22.46X Cap: $7.84B
- View IBB Profile
- View Questions on IBB
IDEXX Laboratories Inc. (IDXX $528.79)
- $528.79 P/E (TTM): 38.91X Cap: $41.71B
- View IDXX Profile
- View Questions on IDXX
Halozyme Therapeutics Inc. (HALO $67.12)
- $67.12 P/E (TTM): 23.8X Cap: $7.96B
- View HALO Profile
- View Questions on HALO
Incyte Corporation (INCY $95.31)
- $95.31 P/E (TTM): 14.87X Cap: $19.03B
- View INCY Profile
- View Questions on INCY
Catalyst Pharmaceuticals Inc. (CPRX $31.18)
- $31.18 P/E (TTM): 17.92X Cap: $3.81B
- View CPRX Profile
- View Questions on CPRX
Gilead Sciences CDR (CAD Hedged) (GILD $26.34)
- $26.34 P/E (TTM): 19.11X Cap: $219.03B
- View GILD Profile
- View Questions on GILD

Q: We have accumulated 11 healthcare stocks and 1 ETF, While LLY and ISRG are at half positions the rest are at initial 25% positions. Please advise [help!] us get to a more concentrated portfolio with a 3+ year horizon for reasonable opportunities in healthcare

Read Answer Asked by sam on January 13, 2026

Adobe Inc. (ADBE $247.60)
- $247.60 P/E (TTM): 14.43X Cap: $100.07B
- View ADBE Profile
- View Questions on ADBE
Accenture plc Class A (Ireland) (ACN $168.82)
- $168.82 P/E (TTM): 13.83X Cap: $112.28B
- View ACN Profile
- View Questions on ACN
Nike Inc. (NKE $41.88)
- $41.88 P/E (TTM): 27.74X Cap: $62.01B
- View NKE Profile
- View Questions on NKE
Thermo Fisher Scientific Inc (TMO $438.34)
- $438.34 P/E (TTM): 24.1X Cap: $162.89B
- View TMO Profile
- View Questions on TMO
TELUS Corporation (T $16.79)
- $16.79 P/E (TTM): 27.98X Cap: $26.21B
- View T Profile
- View Questions on T
IDEXX Laboratories Inc. (IDXX $528.79)
- $528.79 P/E (TTM): 38.91X Cap: $41.71B
- View IDXX Profile
- View Questions on IDXX

Q: Dear 5i,

I have a diverse portfolio with stocks and ETFs. Most of my portfolio is doing well. Want to know your thoughts about a few of my holdings that are not doing so well - Adobe, Nike, Accenture, TMO, IDXX and Telus.

What are your thoughts? Should I replace these with a US ETF or hold on. Thanks for your valuable advice as always.

Read Answer Asked by Alka on November 26, 2025

IDEXX Laboratories Inc. (IDXX $528.79)
- $528.79 P/E (TTM): 38.91X Cap: $41.71B
- View IDXX Profile
- View Questions on IDXX

Q: I bought half a position in IDEXX about a month ago, they recently had about a 25% pop after their results. Would you be comfortable for me adding to my position here?

Read Answer Asked by Andrew on August 11, 2025